No Data
Lianhuan Pharmaceutical: Summary of Lianhuan Pharmaceutical\'s 2024 Annual Report
Lianhuan Pharmaceutical: Lianhuan Pharmaceutical 2024 Annual Report
Lianhuan Pharmaceutical Annual Report 2024
Summary of Lianhuan Pharmaceutical\'s 2024 Annual Report
Jiangsu Lianhuan Pharmaceutical (600513.SH): plans to increase the registered capital of Lianhuan (Anqing) by 80 million yuan.
On April 17, Gelonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company intends to increase the registered capital of Lianhuan (Anqing) by 80 million yuan using its own funds. After this capital increase is completed, the registered capital of Jiangsu Lianhuan Pharmaceutical (Anqing) Co., Ltd. will increase from 50 million yuan to 130 million yuan.
Jiangsu Lianhuan Pharmaceutical (600513.SH): The net income for 2024 is 84.16 million yuan, a year-on-year decrease of 37.66%.
On April 17th, Gelonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced its annual report for 2024. In 2024, the company achieved revenue of 2.16 billion yuan, a year-on-year decrease of 0.63%; achieved net income attributable to shareholders of 84.16 million yuan, a year-on-year decrease of 37.66%; and basic EPS of 0.29 yuan. It plans to distribute a cash dividend of 0.89 yuan (including tax) for every 10 shares to all shareholders. The decline in net income attributable to shareholders for this period of 37.66% is mainly due to a significant increase in R&D investment; additionally, some subsidiaries had higher R&D expenditures, resulting in a decrease in investment income compared to the previous year. At the same time, the company was affected by healthcare policies and market demand.
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
